AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment

AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating ... Read More